Double-Punch cancer trial seeks to extend lives and predict success
NCT ID NCT04892849
Summary
This study is testing if combining immunotherapy drugs (called PD-1/PD-L1 inhibitors) with targeted radiation is more effective for controlling several advanced cancers, including lung and head/neck cancers. It aims to help patients live longer and also tries to find patterns in blood tests that can predict which patients will respond best to this combination treatment. The trial will enroll about 200 adults who are already eligible for this type of immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Radiation Oncology, Universitätsklinikum Erlangen
RECRUITINGErlangen, Bavaria, 91054, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.